HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 24, No 12, December 2019 – Precision Medicine for Brain Tumours       » First Alzheimer's drug to be approved in 17 years holds promise for treatment       » Tencent make medical information readily available to the public       » United States FDA approves first China-made cancer drug       » Value-Based Healthcare: A Paradigm Shift for Better Patient Outcomes       » Precision Agriculture for Future Nutritional Needs      
INSIDE INDUSTRY
ACT Genomics opens third laboratory in Asia at Hong Kong Science Park
Strives to change the cancer treatment model in Hong Kong and ready to tap into tremendous opportunities in the Greater Bay Area.

ACT Genomics, a leading cancer precision treatment solution provider, opened its third Next Generation Sequencing (NGS) laboratory in Asia at Hong Kong Science Park, an innovation and technology centre spearheaded by the Hong Kong Science and Technology Parks Corporation. (HKSTP) The opening ceremony was officiated by Ms Annie Choi, Commissioner for Innovation and Technology; Mr Albert WONG, Chief Executive Officer of HKSTP; together with Dr Chen Hua Chien, Chief Executive Officer, Dr Chen Shu Jen, Chief Scientific Officer, and Mr Victor Chan, Chief Financial Officer of ACT Genomics.

Founded in Taiwan in 2014, ACT Genomics provides cancer patients with personalized genomic information-based treatment plans through its cutting-edge NGS platform, medical reporting, and integrated services. The platform can detect multiple genomic alterations using a single tissue sample within a test run. When used together with bioinformatics analysis tools, curated proprietary medical informatic databases and data visualization technologies, it can match identified mutations with approved and targeted therapies in clinical trials, thus facilitating precise treatments. Apart from the laboratory in Hong Kong, the Group also has laboratories in Taiwan and Japan serving the Asia market. With more than 7,800 samples sequenced, the Group has built a comprehensive cancer genomic database in Asia covering 20 different types of cancer.

The new NGS laboratory of the Group in Hong Kong is equipped with dual sequencing platforms, which boast quicker turnaround time and high throughput. With roughly 7,000 square feet the laboratory is supported by workforce of about 40 responsible for sales, medical science and research and laboratory work. It is designed and built to serve the clinical, pharmaceutical and research communities in the city and Asia, and aspires to capture the opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area in the future.

ACT Genomics believes that the Hong Kong Science Park, dedicated to supporting deep tech enterprises and availing to them all necessary facilities and services, making it an ideal location for ACT Genomics’ new NGS laboratory. In addition to having the support of quality infrastructure, the thriving biotech community there will also present to ACT Genomics abundant collaboration and co-innovation opportunities. Moreover, this Hong Kong laboratory will serve as the ACT Genomics’ corporate finance headquarters, helping it foster closer ties with the investment community in the city deemed an international financial hub.

Click here for the complete issue.

NEWS CRUNCH  
news Proteona awards grant to clinician-scientist for research in treatment selection of multiple myeloma
news Technology giant, Tencent Holdings Limited, promotes medical science and healthcare
news ECV2019 China Healthcare and Pharma Digital Innovation Summit Held Successfully in Shanghai — The "Highway" Era of Healthcare Digital Transformation
news Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
PR NEWSWIRE  
Asia Pacific Biotech News
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
October:
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
November:
Evaluating cost effectiveness of genomic profiling
December:
Precision Medicine for Brain Tumours
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy